Acomhal Research Inc. has successfully completed its residency at the Roanoke-Blacksburg Accelerator Mentoring Program (RAMP) Biotech Accelerator. This milestone marks a significant step forward for the Virginia Tech spinoff company, which is dedicated to developing innovative treatments for aggressive cancers, including glioblastoma.

During the RAMP residency, Acomhal Research benefited from expert mentorship, business development resources, and access to a network of industry leaders. This support has been instrumental in advancing the company’s mission to translate groundbreaking research into effective cancer therapies.

“We are grateful for the opportunity to be part of the RAMP Biotech Accelerator,” said Samy Lamouille, CEO of Acomhal Research. “The mentorship and resources provided have been invaluable in helping us refine our business strategy and accelerate our research and development efforts.”

Mary Miller, executive director of RAMP, praised Acomhal’s progress. “Dr. Lamouille is foremost a fantastic researcher. But not all researchers have the time, desire, or ability to become company owners. Samy has aptitude for it and embraced it. We could not be prouder that we were able to give him a place to get started, help him get all the structures in place a business needs, and help set the foundation for Acomhal as a company.”

Acomhal Research’s completion of the RAMP residency underscores its commitment to advancing cancer treatment through cutting-edge research and entrepreneurial excellence.